Le NPK, Channabasappa S, Hossain M, Liu L, Singh B. Leukocytespecific protein 1 regulates neutrophil recruitment in acute lung inflammation. Am J Physiol Lung Cell Mol Physiol 309: L995-L1008, 2015. First published August 28, 2015 doi:10.1152/ajplung.00068.2014.-The mechanisms of excessive migration of activated neutrophils into inflamed lungs, credited with tissue damage, are not fully understood. We explored the hitherto unknown expression of leukocyte-specific protein 1 (LSP1) in human and mouse lungs and neutrophils and examined its role in neutrophil migration in acute lung inflammation. Autopsied septic human lungs showed increased LSP1 labeling in epithelium, endothelium, and leukocytes, including in their nuclei compared with normal lungs. We induced acute lung inflammation through intranasal administration of E. coli lipopolysaccharide (LPS) (80 g) in LSP1-deficient (Lsp1 Ϫ/Ϫ ) and wild-type (WT) 129/SvJ mice. Immunocytochemistry and Western blots showed increased expression of LSP1 and phosphorylated LSP1 in lungs of LPS-treated WT mice. Histology showed more congestion, inflammation, and Gr-1 ϩ neutrophils in lung of WT mice than Lsp1 Ϫ/Ϫ mice. LPStreated WT mice had significantly more neutrophils in bronchoalveolar lavage (BAL) and myeloperoxidase levels in lungs compared with Lsp1 Ϫ/Ϫ mice. However, there were no differences in lung tissue and BAL concentrations of keratinocyte-derived chemokine, monocyte chemoattractant protein-1, macrophage inflammatory protein-1␣ and -1␤, vascular permeability, and phosphorylated p38 MAPK between LPStreated WT and Lsp1 Ϫ/Ϫ mice, whereas TNF-␣ concentration was higher in BAL fluid from LPS-treated WT. Immunoelectron microscopy showed increased LSP1 in the nuclei of LPS-treated neutrophils. We also found increased levels of phosphorylated LSP1 associated with plasma membrane, nucleus, and cytosol at various times after LPS treatment of murine bone marrow-derived neutrophils, suggesting its role in modulation of neutrophil cytoskeleton and the membrane. These data collectively show increased expression of LSP1 in inflamed mouse and human lungs and its role in neutrophil recruitment and lung inflammation.
by pathogens, such as Mannheimia hemolytica, Streptococcus pneumonia, and E. coli run into billions of dollars (12, 38, 43) . The most common signs of ALI include impaired blood oxygenation, exuberant migration of activated neutrophils into inflamed lungs, and an increase in permeability of the alveolar capillary wall, resulting in edema (6, 53) . Because of the mortality, morbidity, and economic losses, it is crucial to understand the molecular mechanisms for the development of better therapeutics for managing respiratory diseases.
Neutrophils are prominent players in ALI (56) . The migration of activated neutrophils follows a molecular cascade that involves many surface adhesive molecules expressed in response to inflammatory mediators on these leukocytes and the endothelium (38) . In addition, the neutrophils reconfigure their shapes through modulation of their cytoskeleton to navigate the vasculature, such as the tortuous capillary network in the lung, the vascular barrier, and the interstitium (17) . The migrating neutrophils undergo increased polymerization of F-actin under the plasma membrane to induce shape changes in the neutrophils to facilitate their locomotion (13, 38) . The activated neutrophils release cytotoxic chemicals, such as proteases, reactive oxygen species (9) , leukotrienes, proinflammatory cytokines, platelet-activating factor, and procoagulant molecules that disrupt the barrier, leading to an increase in vascular permeability (13, 38) . It is evident that, while neutrophils play an important role in host defense, including in the lung, the excessive migration of activated neutrophils and their products during ALI cause many unwanted tissue effects that are associated with mortality and morbidity (5, 13) . Therefore, it is important to develop new molecular interventions to fine-tune the migration of neutrophils into inflamed lungs to balance their defensive functions against their deleterious actions. However, to achieve this goal, it is essential to have a deeper understanding of the role of the molecules that may regulate neutrophil migration into the inflamed lungs.
Leukocyte-specific protein 1 (LSP1) was discovered in 1988 and is expressed in many cell types, including pre-B cells, B cells, concanavalin A-stimulated murine thymocytes, monocytes, macrophages, neutrophils, and endothelium (3, 24, 33, 49, 67) . In humans, this protein is coded by the gene located at p15·5 on chromosome 11, which has 67% homology to the mouse gene (26, 39) . LSP1 acts as a major downstream substrate of p38 mitogen-activated protein kinase (p38 MAPK), as well as protein kinase C (33) . The COOH terminal of LSP1 is responsible for linking LSP1 with the cytoskeleton, especially F-actin, in the filopodia, lamellipodia, ruffles, and the actin-rich cell cortex of neutrophils during their chemotaxis in vitro (14, 67, 68) . LSP1 was reported to play an important role in leukocyte chemotaxis into inflamed organs, such as cremaster muscle, peritoneum, knee joint, and skin (31, 33, 65) . Recent data show a function for LSP1 in dome formation of endothelium in vivo (48) . Additionally, LSP1 also affects superoxide production by neutrophils (14) . Taken together, LSP1 appears to have important roles as a signaling molecule to modulate the behavior of normal and activated neutrophils and endothelium (33) .
However, to our knowledge, there are no published data on the expression of LSP1 in normal and inflamed lungs or its role in the recruitment of neutrophils in inflamed lungs. Therefore, we performed a series of experiments to study the biology of LSP1 in an ALI murine model. We hypothesized that LSP1 expression is increased in inflamed lungs, and that absence of LSP1 reduces ALI in mice through inhibition of neutrophil recruitment. In this study, the hypothesis is proven true, and LSP1 has an important role in neutrophil recruitment during ALI.
MATERIALS AND METHODS

Materials. Generated Lsp1
Ϫ/Ϫ mice (25) and the wild-type (WT) control 129/SvJ mice were obtained from Dr. Jenny Jongstra-Bilen at University of Toronto. Autopsied normal and septic human lungs (N ϭ 5 in each group) were obtained from the Department of Pathology in the College of Medicine, University of Saskatchewan. Ketamine hydrochloride (Vetalar injection USP, Bioniche, Belleville, ON, Canada), xylazine (Rompun, Bayer, Toronto, ON, Canada), LPS from E. coli 055:B5 (Sigma-Aldrich, St. Louis, MO), rabbit anti-mouse LSP1 polyclonal antibody, reactive in mouse and human (Novus Biological, Oakville, ON, Canada), purified rat anti-mouse Gr-1 antibody (BD Biosciences Pharminogen, Mississauga, ON, Canada), secondary antibody polyclonal goat anti-rabbit immunoglobulins/horseradish peroxidase (HRP), secondary antibody polyclonal rabbit anti-rat immunoglobulins/HRP, primary antibody polyclonal rabbit anti-human von Willebrand factor (Dako, Burlington, ON, Canada), Vector VIP peroxidase substrate kit for peroxidase (Vector Laboratories, Burlingame, CA), myeloperoxidase (MPO) standard from human leukocytes (Sigma-Aldrich, St. Louis, MO), and Bio-Plex Pro assays kit (Bio-Rad, Mississauga, ON, Canada) were purchased commercially.
Murine model of ALI. Twelve-to sixteen-week-old male WT 129/SvJ and Lsp1 Ϫ/Ϫ mice were used. The ALI experimental protocol was approved by the University of Saskatchewan's Animal Research Ethics Board and adhered to the Canadian Council on Animal Care guidelines. All mice were housed in a 12:12-h dark-light cycle and fed standard laboratory diet in Lab Animal Services Unit, University of Saskatchewan.
A murine model of LPS-induced ALI was used as described previously (59, 60) . Briefly, 80 g of LPS in 80 l saline were instilled intranasally into each mouse to induce ALI in WT (N ϭ 10) . LSP1 staining (arrows) is observed in alveolar septum and alveolar macrophages (C) and leukocytes (E) in lungs from a nonseptic human. D and F: increased number of neutrophils expressing LSP1 (arrows), especially in the nuclei (F), recruited into a septic lung. G: statistical analysis of semiquantitative LSP1 expression scoring of human lung sections shows increased (*P Ͻ 0.05; n ϭ 5) LSP1 expression in macrophages, neutrophils, endothelium, and airway epithelium of septic human lungs compared with normal control human lungs. We classified the intensity of staining as follows: 0, no staining; 1ϩ, light staining; 2ϩ, moderate staining; 3ϩ, strong staining; and 4ϩ, very strong staining. Magnification: ϫ400 and ϫ1,000.
and Lsp1 Ϫ/Ϫ mice (N ϭ 11). Saline (0.9% NaCl, 80 l/mouse) was used as a sham for WT (N ϭ 7) and Lsp1 Ϫ/Ϫ (N ϭ 10) negative control groups. At 9 h after LPS treatment, immediately following intraperitoneal injection of 100 mg/kg ketamine and 10 mg/kg xylazine, cardiac blood, lungs, and bronchoalveolar lavage (BAL) fluid were collected from the mice. To examine the expression of LSP1 in the lungs, we also collected mouse lungs after 12 and 24 h of intranasal LPS treatment.
Blood and BAL cell counts. After trachea was exposed, the lungs were lavaged three times with 0.5 ml of cold HBSS with NaHCO 3 (Sigma-Aldrich), and the BAL was centrifuged at 1,500 g for 10 min at 4°C. Supernatants were collected and stored at Ϫ80°C for protein, chemokine, and cytokine detection. Total leukocytes in BAL fluid were counted and resuspended at 10 6 /ml with HBSS. One hundred microliters of these solutions were cytospun onto slides, and cells were stained with Hemacolor stain kit (EMD Chemicals, Gibbstown, NJ) for differential leukocyte count in four random fields at ϫ400.
Mouse peripheral blood collected through cardiac puncture was kept in heparinized tubes. The total number of leukocytes per milliliter of blood was counted after erythrocyte hemolysis with 2% acetic acid. Simultaneously, blood smear was stained with Hemacolor stain kit for differential leukocyte count in 10 fields at ϫ400.
Cytokine and chemokine analyses in BAL fluid and lung homogenates. We quantified keratinocyte-derived chemokine (KC), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1␣ (MIP-1␣), MIP-1␤, and tumor necrosis factor-␣ (TNF-␣) in right lungs and BAL fluid collected from the mice with Bio-Plex Pro Assay Kit (Bio-Rad) following manufacturer's instructions.
Pulmonary vascular permeability assay. Protein analysis in BAL fluid was carried out to evaluate vascular permeability by using protein assay dye reagent concentration kit (Bio-Rad), following the manufacturer's instructions. The principle of protein determination was according to the Bradford method (2) .
Histopathological analysis. Right bronchus of mouse lung was ligated with a thread before left lung was instilled with 1 ml of cold 4% paraformaldehyde in situ through the trachea. After left lung was inflated, right lung was cut and stored at Ϫ80°C for analysis later on. Left lung was fixed in 4% paraformaldehyde, processed, and embedded in paraffin. All sections (5 m thickness) were placed on poly-L-lysine-coated glass slides and stained with hematoxylin and eosin for histopathological examination. Histopathology scoring was adopted from previous description (60) . shows LSP1 expression increases in macrophages, neutrophils, endothelium, and airway epithelium after 9-, 12-, and 24-h LPS challenge compared with saline-treated controls (*P Ͻ 0.05; n ϭ 5). The intensity of staining was graded as follows: 0, no staining; 1ϩ, light staining; 2ϩ, moderate staining; 3ϩ, strong staining; and 4ϩ, very strong staining. Magnification: ϫ400 and ϫ1,000.
Lung MPO quantification. MPO assay was performed following a previous protocol (55) . Briefly, the lung homogenates in 50 mM HEPES (Invitrogen, Burlington, ON, Canada) were centrifuged at 900 g for 20 min at 4°C, and the pellet was resuspended and rehomogenized in 0.5% cetyltrimethyl ammonium chloride solution. MPO colorimetric assay was performed using 3,3=,5,5=-tetramethylbenzidine as the substrate for H 2O2 under low pH conditions. Reaction was terminated by 1 M H2SO4 and read at 450 nm outer diameter by NOVOstar software (Bio-Rad). Data are expressed as units of MPO per milligram of lung tissue.
LSP1 and Gr-1 immunohistochemistry. The immunohistochemistry protocol was modified from a previous paper (54) . Briefly, sections were deparaffinized, followed by quenching of the endogenous peroxidase activity and treatment with pepsin. Following 1-h blocking with 1% BSA, the sections were incubated with primary antibody (20 g/ml LSP1 antibody, 0.40 g/ml anti-Gr-1 antibody) and appropriate secondary antibody (1.5 g/ml polyclonal goat anti-rabbit immunoglobulins/HRP, 13 g/ml polyclonal rabbit anti-rat immunoglobulins/HRP). The color development was carried out with Vector VIP peroxidase substrate kit. While some sections were stained with methyl green, the others were examined without nuclear staining to assess whether LSP1 is present in the nucleus. The controls included staining with the anti-endothelial marker von Willebrand factor serving as a positive control, or isotype antibody matching control (rabbit IgG or rat IgG2b, -antibody) instead of primary antibody or omission of primary antibody serving as negative controls. Also, Lsp1 Ϫ/Ϫ murine lungs stained with LSP1 antibody acted as an important negative control for the nonspecific staining by the antibody.
Western blot analyses for pLSP1, LSP1, phosphorylated p38 (pp38) MAPK, and p38 MAPK. Frozen mouse lungs were homogenized in the protease and phosphatase inhibitor cocktail, T-PER Tissue Protein Extraction Reagent (Thermo Scientific, Rockford, IL), as described (22) . The Western blot procedure was modified from a previous protocol (20) . We first probed for phosphorylated LSP1 (pLSP1) (n ϭ 6 each group). The membranes were incubated with pLSP1 p-Ser252 antibody (1:500, Novus Biological) and secondary polyclonal goat anti-rabbit immunoglobulins/HRP (1:2,000, Dako). Incubation without primary antibody was used as a negative control. Also, lung lysates from Lsp1 Ϫ/Ϫ mice incubated with LSP1 antibody acted as a negative control for the nonspecific binding by the LSP1 antibody. The detection blots were performed with Amersham ECL Western blotting detection reagents kit (GE Healthcare, Freiburg, Germany). Finally, the membranes were exposed under autoradiography Hyperfilm ECL (GE Healthcare). For detection of total LSP1, the probed membrane was stripped with blot restore membrane rejuvenation kit (Millipore, Billerica, MA) before reprobing with polyclonal rabbit anti-mouse LSP1 antibody (1:500, Novus Biological) and secondary polyclonal goat anti-rabbit immunoglobulins/HRP, as above.
To detect total and pp38 MAPK (n ϭ 4 each group), membranes were incubated with purified monoclonal rabbit anti-phospho-p38 MAPK (Thr180/Tyr182) antibody (1:1,000, Cell Signaling Technology, Danvers, MA) at 4°C with gentle shaking overnight and secondary polyclonal goat anti-rabbit immunoglobulins/HRP for 1 h (1: Fig. 3 . Immuno-gold electron microscopy for LSP1 of a mouse lung. Transmission electron micrograph of a mouse lung 9 h post-LPS treatment shows staining for LSP1 in plasma membrane, nucleus, and cytoplasm of a neutrophil (N, red arrows), an endothelial cell (E, blue arrows), and type I pneumocytes (p1, yellow arrows). As, alveolar space. Original magnification ϫ20,000.
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Total LSP1 (52 kD) Western blots performed on mouse lungs 9 h post-LPS treatment show pLSP1 and total LSP1 in WT but not Lsp1 Ϫ/Ϫ express at ϳ52 kDa. ␤-Actin, a housekeeping gene protein (47 kDa), was used for loading control. The densitometric analyses showed increased pLSP1 as ratio of ␤-actin (B) and total LSP1 (C), and increased pLSP1 over total LSP1 (D) in LPS-treated WT mice. Values are means Ϯ SE. *Significant difference from WT saline controls (P Ͻ 0.05, n ϭ 6).
2,000, Dako). For total p38 MAPK detection, the probed membranes were stripped with blot restore membrane rejuvenation kit before being reprobed with purified rabbit anti-p38 MAPK antibody (1: 10,000, Enzo Life Sciences, Farmingdale, NY) and secondary polyclonal goat anti-rabbit immunoglobulins/HRP, as above.
Finally, all membranes were stripped again and incubated with affinity purified rabbit anti-␤-actin antibody (1:5,000, ABCAM, Cambridge, MA) and secondary antibody polyclonal goat anti-rabbit immunoglobulins/HRP. ␤-Actin was used to determine the equal total amount of protein loaded for each sample. Densitometric quantification was performed using ImageJ software to evaluate relative density of pLSP1, total LSP1, pp38 MAPK, and total p38 MAPK expression levels against ␤-actin loading controls, and some times as ratios of phosphorylated proteins against total protein.
Murine bone marrow neutrophil isolation. Murine neutrophils were isolated as described previously (32) . Briefly, entire femur and tibia bones were collected from the mice and cleared of any associated tissues. After the ends of the bones were removed, the bone marrow was thoroughly flushed with ice-cold PBS free of Ca 2ϩ and Mg 2ϩ until the bones became visibly clear and white. The morphologically mature neutrophils were isolated through the use of a three-step Percoll gradient of 72%, 64%, and 52% (GE Healthcare, Uppsala, Sweden). Neutrophils were collected by centrifuging at 1,060 g for 30 min and suspending in 1 ml of RPMI 1640 medium (Lonza). pLSP1, LSP1 in subcellular fractionations of murine bone marrow neutrophils. The isolated murine bone marrow neutrophils were treated with LPS for 10, 30, 60, and 90 min. This was followed by isolation and collection of cytosolic, membrane/organelle, nuclear, and cytoskeletal fractions using a protocol provided by the manufacturer (Calbiochem ProteoExtract Subcellular Extraction Kit/EMD Biosciences). The protocol included the use of benzonase, protease inhibitor cocktail (Merck KGaA, Darmstadt, Germany), and phosphatase inhibitor cocktail (Fisher Scientific, ON, Canada). The extracted proteins were added to 4ϫ sample buffer for Western blotting for pLSP1 and total LSP1 expression, as described previously (20) . Densitometry from four separate experiments was performed using ImageJ software to evaluate relative density of pLSP1, total LSP1 expression level. Control group value was brought to 1, and other treated groups were indicated as times in each membrane (fold change).
Human neutrophil isolation. Human venous blood was collected from healthy volunteers, and neutrophils were isolated based on density gradient principle, as described (34) . Histopaque H1119, H1083, and H1077 (Sigma-Aldrich), with density of 1.119, 1.083, and 1.077 g/ml, respectively, were carefully overlaid in order from the bottom to the top, and blood was placed in the uppermost. After being centrifuged at 700 g for 10 min in 4°C, neutrophils were aspirated in the layer between H1083 and H1119. The collection was centrifuged at 700 g for 10 min in 4°C for collecting the pellet that had neutrophils. Erythrocyte contaminants were lysed isotonically with distilled water, and neutrophils were washed twice with PBS (pH ϭ 7.2) before being resuspended in 1 ml RPMI 1640 medium (Lonza). Both the viability and purity of isolated neutrophils were more than 95%.
Immuno-gold electron microscopy. Human neutrophils and mouse lungs were assessed for the expression of LSP1. The isolated neutrophils and mouse lungs were fixed in 2% paraformaldehyde with 0.1% glutaraldehyde in 0.1 M sodium cacodylate buffer for 3 h at 4°C. After being dehydrated, the neutrophils and mouse lungs were infiltrated in white resin. Next, samples were sectioned into 100-nm thickness on nickel grids. Nonspecific bindings were blocked by BSA 1% in Tris-buffered saline before 1-h incubation in LSP1 antibody (40 g/ml). Negative control without primary antibody was also examined. After three times being washed in Tris-buffered saline, the sections were incubated for 1 h in 20-nm gold-conjugated anti-rabbit secondary antibody with 1:100 dilution. Following that, samples were incubated in 2% aqueous uranyl acetate, an indicator for negative staining, then Reynold's lead citrate to enhance the electron-scattering Ϫ/Ϫ mouse lungs challenged with LPS (D). Lesions were scored for both severity of inflammatory cell infiltration and distribution under magnification ϫ1,000: 0, normal lung architecture; 1, minimal, diffuse reaction in alveolar walls, congestion, 1-10 neutrophils/field in peribronchial vascular space; 2, mild, 11-20 neutrophils/field, congestion, slight thickening alveolar wall; 3, moderate, 21-30 neutrophils/ field, congestion, thickening alveolar wall, light epithelial damage; 4, severe, Ն31 neutrophils/field, congestion, thickening alveolar wall with more than 10% of lung consolidated, epithelial damage. E: statistical analysis of semiquantitative scoring shows more inflammation (*P Ͻ 0.05) in LPS-treated WT and Lsp1 Ϫ/Ϫ mice compared with their respective saline-treated controls, and in LPS-treated WT mice compared with Lsp1 Ϫ/Ϫ mice. F: analysis of protein concentration in bronchoalveolar lavage (BAL) fluid shows that both types of mice challenged with LPS showed significantly higher protein concentration than saline-treated control, but there was no difference between WT and Lsp1 Ϫ/Ϫ mice. Bv, blood vessel; Br, bronchiole. Magnification: ϫ100.
properties of biological components inside the cells. The micrographs were imaged using EM410 electron microscope (Philips, Holland) operated at 60 kV. The gold particles in the nuclei of normal and activated neutrophils were counted. Statistical analysis. Statistical analysis was performed using GraphPad Prism software version 5.04 (San Diego, CA). Quantitative results were expressed as means Ϯ SE. Normal distribution of residuals was tested by histogram and Shapiro-Wilk test. Data were analyzed by ANOVA, followed by Bonferroni multiple-comparison test. Student t-test or Wilcoxon signed rank test was used to compare two groups. The critical value of ␣ was set to 0.05 as a significant difference (two-tailed).
RESULTS
LSP1 expression is increased in septic human lungs. To our knowledge, there was no information on LSP1 expression in normal human lungs. Therefore, we used immunohistochemistry to bridge this gap. Autopsied normal human lungs showed LSP1 staining in alveolar septum, alveolar macrophages, and leukocytes ( Fig. 1, C and E) . Septic lungs showed massive neutrophil emigration and the obliteration of normal lung architecture. Neutrophils in the alveoli and blood vessels showed robust expression of LSP1 (Fig. 1, D and F) . Interestingly, LSP1 was extensively localized into the nuclei of neutrophils, and the staining was more intense in nucleus than in cytoplasm (Fig. 1F) . Because autopsied human lung tissues likely were not sampled in a consistent manner, we resorted to only semiquantification of immunohistochemical LSP1 staining, which revealed an increase in LSP1 staining in airway epithelium, endothelium, neutrophils, and macrophages in all of the septic human lungs compared with the normal human lung controls ( Fig. 1G ; P Ͻ 0.05).
LSP1 expression is increased in LPS-induced lung inflammation in mouse.
After examining the LSP1 expression in human lungs, we explored LSP1 expression in lungs from normal control mice and compared it to LSP1 expression in mice with LPS-induced ALI. The immunohistochemical controls include staining lungs from Lsp Ϫ/Ϫ mice with LSP1 antibody (Fig. 2B) . In contrast to saline-treated mice lungs (Fig. 2, C, E, and G) , the inflamed lungs showed increased labeling for LSP1 on alveolar septa, airway epithelium, and vascular endothelium at 9 h post-LPS treatment (Fig. 2, D, F,  and H) . In particular, the staining was intense in neutrophils, macrophages, and airway epithelium of the LPS-treated mice. The expression of LSP1 remained strong in bronchiolar epithelium (Fig. 2, I and K) and vascular endothelium (Fig. 2J ) at 12 and 24 h post-LPS treatment. Similar to the observation on human lungs, the LSP1 was localized in nuclei of airway epithelial cells, macrophages, and neutrophils, as well as neutrophils trapped in the epithelium (Fig. 2K) , as well as under the endothelium (Fig. 2H) , in lungs of LPS-treated mice (Fig.  2, K and L) . The semiquantification showed an increase in LSP1 staining in lungs from mice treated with LPS compared with the saline-treated controls ( Fig. 2M ; P Ͻ 0.05). Because of resolution limitations of light microscopy, we performed immunoelectron microscopy on mouse lungs. The ultrastructural observations confirmed the presence of LSP1 in endothelial cells, epithelial cells, and neutrophils in the lungs of LPS-treated mouse (Fig. 3) . 
Phosphorylated and total LSP1 expression is increased in LPS-induced lung inflammation in mouse.
We used Western blots to compare the levels of LSP1 expression in normal and the 9-h post-LPS-treated lungs in mice. While Western blots confirmed the lack of LSP1 protein in the Lsp1 Ϫ/Ϫ mice, the expression of phosphorylated as well as total LSP1 in lung tissues was significantly increased in lungs of WT mice at 9 h of LPS treatment compared with strain-matched saline controls (Fig. 4) .
LSP1 deficiency reduces histological signs of lung inflammation. To determine the role of LSP1 in ALI, we conducted histopathological assessment on lungs collected from LPS-treated mice in this study. Hematoxylin-and eosin-stained lungs (Fig.  5 ) from saline-treated WT (Fig. 5A) or Lsp1 Ϫ/Ϫ mice (Fig. 5B ) showed normal architecture, whereas lungs from LPS-treated WT mice (Fig. 5C ) had congestion, damage to epithelium, and infiltration of neutrophils in the septa and perivascular spaces.
The lungs from Lsp1
Ϫ/Ϫ mice treated with LPS ( Fig. 5D ) showed considerably less inflammation and histopathology compared with LPS-treated lungs from WT mice. The extent of histological differences was also indicated by the fact that, even after the lavage, the lungs from LPS-treated WT mice had many more neutrophils in the alveoli compared with LPStreated lungs from Lsp1 Ϫ/Ϫ mice. Semiquantitative grading of histopathology showed significantly more inflammation in lungs of WT mice treated with LPS compared with Lsp1 Ϫ/Ϫ mice.
LSP1 deficiency does not affect vascular permeability in inflamed lungs.
In the LPS-administered animals, protein concentration in BAL fluid increased compared with saline control in both types of mice (P Ͻ 0.01) (Fig. 5F ). However, there was no significant difference in protein levels between WT and Lsp1 Ϫ/Ϫ mice after treatment with LPS. This suggests that LSP1 deficiency does not affect lung vascular permeability in acute lung inflammation at this time point.
LSP1 deficiency reduces neutrophil recruitment into inflamed lungs. We examined the role of LSP1 in LPS-induced recruitment of neutrophils into lung alveoli. As depicted in Fig.  6 , A-C, LPS treatment increased the numbers of total leukocytes in BAL fluid of WT and Lsp1 Ϫ/Ϫ mice compared with their respective saline-treated controls (WT groups P Ͻ 0.001, Lsp1
Ϫ/Ϫ groups P Ͻ 0.05). Furthermore, the total leukocyte count was higher in BAL fluid from LPS-treated WT mice than from LPS-treated Lsp1 Ϫ/Ϫ mice (P Ͻ 0.001). Similarly, the absolute neutrophil numbers, but not macrophage numbers, were higher in BAL fluid of LPS-treated WT mice compared with LPS-treated Lsp1 Ϫ/Ϫ mice (P Ͻ 0.001). There were no differences in total leukocyte and neutrophil counts in peripheral blood between saline-treated WT and Lsp1 Ϫ/Ϫ mice (Fig. 6, D and F) . Neutrophil numbers in blood in both genotypes of mice post-LPS treatment compared with saline-treated controls were not statistically different (Fig. 6F) . However, peripheral blood neutrophil percentage was higher in WT and Lsp1 Ϫ/Ϫ mice at 9 h post-LPS treatment compared with their respective controls (P Ͻ 0.001). It is known that many neutrophils are trapped in the vasculature or interstitium of inflamed lungs, in addition to those that have migrated into the airways and are flushed with BAL. Therefore, we first obtained morphological evidence of the presence of neutrophils in lung tissues with Gr-1 immunohistochemistry (Fig. 7, A-F) . Based on some recent reports on the importance of perivascular and peribronchial compartments in lung inflammation, we specifically focused on these areas in the lung. The semiquantitative data in the lung sections showed more neutrophils in the alveolar (Fig. 7H ) and perivascular spaces (Fig. 7I ) from LPS-treated WT mice than from LPStreated Lsp1 Ϫ/Ϫ mice. Finally, we used MPO estimation as a surrogate for the lung tissue neutrophils. As shown in Fig. 7G , compared with respective saline controls, higher MPO activity was detected in lungs of LPS-treated WT (P Ͻ 0.001), but not in LPS-treated Lsp1 Ϫ/Ϫ mice. Lungs from LPS-treated WT mice also had higher MPO activity compared with LPS-treated Lsp1 Ϫ/Ϫ mice (P Ͻ 0.05). Ϫ/Ϫ mice treated with LPS. In lung tissues, the LPS treatment of WT and Lsp1 Ϫ/Ϫ mice increased concentrations of KC, MCP-1, MIP-1␣, MIP-1␤, and TNF-␣ compared with their respective saline controls (P Ͻ 0.05). There, however, were no differences in the concentrations of these inflammatory mediators between WT and Lsp1 Ϫ/Ϫ mice upon normal saline treatment or LPS treatment (Fig. 8, bottom) .
LSP1 deficiency reduces the expression of TNF-␣, but not KC, MCP-1, MIP-1␣, or MIP-1␤ in whole lung
p38 MAPK signaling pathway in lungs of WT and Lsp1
Ϫ/Ϫ mice. p38 MAPK is known as an upstream kinase for LSP1 (19, 68) . Inhibition of p38 MAPK reduces endothelial LSP1 phosphorylation (16) . To determine whether differences in phosphorylation of p38 MAPK may underlie the differences in lung inflammation, we performed densitometry on Western blots for phosphorylated Thr180/Tyr182 p38 MAPK (pp38 MAPK) and total p38 MAPK in mouse lungs (Fig. 9A) . The data (Fig. 9 , B and C) show that, in both genotypes of mice, pp38 MAPK levels were increased at 9 h post-LPS treatment compared with respective saline-treated controls (P Ͻ 0.05). However, there was no difference in the amount of pp38 MAPK and total p38 MAPK between lungs of control or LPS-treated WT mice and Lsp1 Ϫ/Ϫ mice, respectively. LSP1 expression in human peripheral blood neutrophils. We further pursued the observation of fine localization of LSP1 in neutrophils in mouse lung capillaries (Fig. 3) with isolated normal and LPS-treated human neutrophils (Fig. 10) . The ultrastructural observations confirmed the presence of LSP1 in nucleus and cytoplasm of the control neutrophils (Fig. 10A) . Compared with the saline-treated neutrophil, the LPS-treated neutrophils had more LSP1 staining in their nucleus, cytoplasm, and plasma membrane (Fig. 10, B and D) . The quanti- fication of gold particles labeling for LSP1 showed a significant increase in nuclear labeling in LPS-treated neutrophils (Fig. 10C) . Expression of LSP1 on membrane, cytosol, nucleus, and cytoskeleton in neutrophils. The LSP1 protein facilitates cytoskeletal and plasma membrane shape changes in endothelium. Because ultrastructural evidence showed changes in LSP1 expressed on plasma membrane of neutrophils, we also investigated the subcellular localization of native and pLSP1 in the cytosol, membrane/organelles, nuclear material, and cytoskeleton obtained from normal and activated neutrophils (Fig. 11) . Western blots illustrate that, in resting neutrophils, LSP1 is mostly expressed in the cytoskeleton, plasma membrane, and cytosol, along with weak expression in the nuclear fraction (Fig. 11) . Ten minutes of LPS treatment increased the expression of native and pLSP1 in plasma membrane. While total LSP1 in the cytosol was increased at 60 min of LPS treatment, cytosolic pLSP1 was increased at 90 min of the treatment. pLSP1 and total LSP1 were also significantly increased in the nucleus of neutrophils compared with the control values at 30 min of LPS treatment. These data show dynamic changes in the localization of LSP1 and pLSP1 between various compartments of activated neutrophils.
DISCUSSION
We provide the first data on the expression and role of LSP1 in LPS-induced ALI. The data show that LSP1 may regulate lung inflammation through an increase in its native and phosphorylated forms, suggesting its role as a signaling molecule, its dynamic association with various cell organelles, and effect on TNF-␣ expression. Interestingly, LSP1 deficiency alters neither the expression of KC, MCP-1, MIP-1␣, and MIP-1␤ in BAL and lung tissues, nor pulmonary microvascular permeability. These data add to our basic understanding of LSP1 expression and function in neutrophil recruitment in inflamed lungs.
There have been limited studies on the expression and role of LSP1 in lung physiology (27, 28, 49) . First, we undertook a detailed investigation of LSP1 expression in normal and inflamed human and mouse lungs. Because we observed an increase in LSP1 expression in epithelium, endothelium, and leukocytes in inflamed human lungs, we used a mouse model of LPS-induced ALI to further study the function of LSP1 in lung inflammation. The inflamed lungs from mice also showed an increase in LSP1 expression in airway epithelium, alveolar macrophages, and septal cells compared with the lungs from control mice. The expression of LSP1 in airway epithelium and inflammatory cells such as neutrophils was increased at 9 h and sustained up to 24 h post-LPS treatment. The semiquantitative increase in LSP1 in inflamed lungs confirmed with Western blots on lung homogenates showed a significant increase in total LSP1 as well as pLSP1. These data show an increase in the amount and activation of LSP1 in ALI, and that increase was recorded in resident as well as recruited cells in inflamed lungs.
There is very limited information available on the subcellular localization of LSP1 (23, 48) . Our immunohistological data showed intense LSP1 expression in nucleus of neutrophils in autopsied septic human lungs. This intriguing observation was further bolstered through immunoelectron microscopy, which showed significant increase in nuclear localization of LSP1 in activated neutrophils compared with the normal neutrophils. Lastly, Western blots demonstrated native and pLSP1 in nuclear fractions isolated from control and activated mouse neutrophils. It has been shown previously that, during neutrophil recruitment, endothelial LSP1 translocated from nucleus and cytosol to the cytoskeleton to form endothelial domes to allow transendothelial migration of neutrophils (48) ; however, this is the first observation on the translocation of LSP1 into the nucleus of activated neutrophils. There have been reports of proteins, such as Toll-like receptor-4 that localize to the nucleus (21) . We need further studies to assess the role of nuclear LSP1.
WTSaline
WT-LPS
Endotoxin-induced lung injury is characterized by migration of neutrophils into lung tissues, and migration of activated neutrophils, although necessary for host defense, is credited with excessive tissue damage. There are studies demonstrating the role of selectins and integrins (15, 69) , along with various chemokines, in recruitment of neutrophils into low microvascular pressure environment of the lungs (1, 50 -52, 66) . Our data are the first to show that LSP1 deficiency reduces lung pathology and migration of neutrophils into alveoli and interstitium of inflamed lungs. While migration of neutrophils into alveoli is important, the neutrophils still trapped in lung interstitium are also active and cause significant tissue damage. Therefore, reduction in recruitment of activated neutrophils into alveolar and interstitial compartments of lungs may underlie reduced inflammation and histopathology.
The Lsp1
Ϫ/Ϫ and WT mice used in this study developed normally, and the Lsp1 Ϫ/Ϫ mice were able to mount a pulmonary inflammatory response, although to a lesser degree than the WT mice. The Western blot results indicated that WT and Lsp1 Ϫ/Ϫ mice did not have a significant difference in baseline pp38 MAPK. LPS treatment caused significant increases in pp38 MAPK in both WT and Lsp Ϫ/Ϫ mice. These data suggest that LSP1 deficiency did not affect MAPK signaling pathway, which is upstream of LSP1.
To further understand the mechanisms of reduced neutrophil migration in LPS-treated Lsp1 Ϫ/Ϫ mice, we examined BAL and lung tissue expression of KC, MCP-1, MIP-1␣, MIP-1␤, and TNF-␣, which have many important functions on ALI (1, 51, 66) . We found similar increases in concentrations of KC, MCP-1, MIP-1␣, MIP-1␤, and TNF-␣ in lung homogenates of LPS-treated WT and Lsp1 Ϫ/Ϫ mice to suggest no impact of LSP1 deficiency. Because the recruitment of neutrophils into alveoli is directed through chemokines, we also examined KC, MCP-1, MIP-1␣, MIP-1␤, and TNF-␣ concentration in BAL fluid. Except TNF-␣, there was no effect of LSP1 deficiency on secretion of these inflammatory mediators. It is reported that TNF-␣ is produced by activated monocytes, macrophages (40) , and neutrophils, which can induce expression of adhesion molecules on endothelium and leukocytes to attract more neutrophils into inflamed organs (4, 29, 63 ). The role of TNF-␣ on lung inflammation is controversial (58) . Despite the func- tion of TNF-␣ in regulating function and migration of immune cells to protect the host, uncontrolled production of this endogenous pyrogen can induce cell death, overwhelming inflammatory response and tissue injury (18, 45, 47, 62) . While differences in TNF-␣ may not be the major determinant for reduced lung inflammation and neutrophil recruitment in lungs of Lsp1 Ϫ/Ϫ mice, LSP1 protein may have some regulatory function in TNF-␣ production. Nevertheless, the data show that LSP1 regulates neutrophil recruitment into inflamed lungs without altering expression of chemokines examined in this study.
LSP1 phosphorylation increased significantly after 9-h LPS treatment. It is known that the COOH terminal, which also contains phosphorylation sites of LSP1, associates with the cytoskeleton, especially F-actin, of endothelial cells (14) . The reduced migration of neutrophils in Lsp1 Ϫ/Ϫ mice may be due to lack of association of LSP1 with cytoskeleton of neutrophils and endothelium. In this study, we demonstrate localization of LSP1 on both the plasma membranes of neutrophils and endothelial cells with light and electron immunoelectron microscopy. Furthermore, we used Western blots on fractionated LPS-activated neutrophils to show increased localization of pLSP1 on plasma membrane at 10 min and nucleus at 30 min to suggest a potential direct role of LSP1 in plasma membrane modifications of neutrophils. Previously, whole-mount staining of cremaster muscle tissue or two-photon microscopy showed a double-fold increase in the quantity of domes in WT mice than that in Lsp1 Ϫ/Ϫ mice after TNF-␣ or interleukin-1␤ administration (48) . Moreover, transmission electron microscopy illustrated that endothelial domes completely enveloped neutrophils in WT, but not in Lsp1 Ϫ/Ϫ mice (48) . We believe that membrane localization of native and pLSP1 in activated neutrophils in our study may be needed for cytoskeletal rearrangement to influence the plasma membrane modifications needed for their migration and engagement with the endothelium.
Neutrophil migration across the endothelium and increased microvascular permeability are usually linked together. Unexpectedly, we did not find significant differences in vascular permeability in lungs of WT and Lsp1 Ϫ/Ϫ mice treated with LPS. The reasons for this discrepancy in our experiments are not clear, but there are previous data to show that lung vascular permeability may be independent of neutrophil migration (37, 46) . Recently, the peribronchial and perivascular compartments of the lung have become the focus of attention in lung inflammation (64) . While our method determines the leakage of proteins into lung alveoli, the fluid trapped in the perivascular and peribronchial compartments was not measured in our studies and needs to be done in future studies. Based on histological dilatation of perivascular compartment, we speculate whether there was an increase in fluid trapped in lung interstitium. Furthermore, every neutrophil immigrating in KC, TNF-␣, or MIP-2-treated cremaster muscles of Lsp1 Ϫ/Ϫ mice caused significantly higher vascular permeability (30, 31, 48) , which may also have obliterated the differences in vascular permeability between WT and Lsp1 Ϫ/Ϫ mice. Taken together, we present the first detailed data on the expression of LSP1 in normal and inflamed human and mouse lungs. The data also demonstrate that LSP1 deficiency leads to reduced lung inflammation and neutrophil migration, but not vascular permeability or expression of selected chemokines examined in our experiments. Based on the localization of native and pLSP1 in various compartments of activated neutrophils, we speculate that neutrophil LSP1 may have an active role in their migration and may facilitate direct engagement with vascular endothelium or LSP1 expressed on the endothelium (Fig. 12) . Furthermore, the LSP1 expressed in airway and alveolar epithelial cells may also have a role in the migration of neutrophils and generation of inflammation in lungs. Fig. 12 . A schematic depiction of LSP1 expression and its effects in acute lung inflammation. In addition to activating macrophages and epithelium in the airways via binding to Toll-like receptor-4 (TLR4), LPS can activate the capillary endothelium and blood neutrophils following translocation across the air-blood barrier. The activation, for example of MAPK, which use LSP1 as a substrate, is a critical step for neutrophils to modify their cytoskeleton and plasma membrane to migrate. Based on the significance of binding of LSP1 to cytoskeleton in dome formation on endothelial cells, we believe that translocation of pLSP1 to plasma membrane of LPS-activated neutrophils is critical for the engagement of their cytoskeleton (e.g., F-actin) with plasma membrane. The LSP1 deficiency impairs cytoskeletal reorganization in neutrophils and endothelial cells, resulting in reduced migration of neutrophils, as observed in our experiments.
